| PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation K Ezzat, SEL Andaloussi, EM Zaghloul, T Lehto, S Lindberg, PMD Moreno, ... Nucleic acids research 39 (12), 5284-5298, 2011 | 288 | 2011 |
| Genetic therapies for RNA mis-splicing diseases SM Hammond, MJA Wood Trends in Genetics 27 (5), 196-205, 2011 | 262 | 2011 |
| Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment C Betts, AF Saleh, AA Arzumanov, SM Hammond, C Godfrey, ... Molecular Therapy—Nucleic Acids 1 (8), e38, 2012 | 233 | 2012 |
| Delivery of oligonucleotide‐based therapeutics: challenges and opportunities SM Hammond, A Aartsma‐Rus, S Alves, SE Borgos, RAM Buijsen, ... EMBO Molecular Medicine 13 (4), e13243, 2021 | 211 | 2021 |
| Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy SM Hammond, G Hazell, F Shabanpoor, AF Saleh, M Bowerman, ... Proceedings of the National Academy of Sciences 113 (39), 10962-10967, 2016 | 191 | 2016 |
| Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice HF Yin, AF Saleh, C Betts, P Camelliti, Y Seow, S Ashraf, A Arzumanov, ... Molecular Therapy 19 (7), 1295-1303, 2011 | 167 | 2011 |
| How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse C Godfrey, S Muses, G McClorey, KE Wells, T Coursindel, RL Terry, ... Human molecular genetics 24 (15), 4225-4237, 2015 | 141 | 2015 |
| Mouse survival motor neuron alleles that mimic SMN2 splicing and are inducible rescue embryonic lethality early in development but not late SM Hammond, RG Gogliotti, V Rao, A Beauvais, R Kothary, CJ DiDonato PloS one 5 (12), e15887, 2010 | 84 | 2010 |
| Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment MJ Gait, AA Arzumanov, G McClorey, C Godfrey, C Betts, S Hammond, ... Nucleic acid therapeutics 29 (1), 1-12, 2019 | 74 | 2019 |
| Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice CA Betts, AF Saleh, CA Carr, SM Hammond, AML Coenen-Stass, ... Scientific reports 5 (1), 8986, 2015 | 61 | 2015 |
| Molecular and phenotypic reassessment of an infrequently used mouse model for spinal muscular atrophy RG Gogliotti, SM Hammond, C Lutz, CJ DiDonato Biochemical and biophysical research communications 391 (1), 517-522, 2010 | 60 | 2010 |
| PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. SM Hammond, MJ Wood Current opinion in molecular therapeutics 12 (4), 478-486, 2010 | 59 | 2010 |
| Multiple isoforms of the KC1 cotransporter are expressed in sickle and normal erythroid cells SC Crable, SM Hammond, R Papes, RK Rettig, GP Zhou, PG Gallagher, ... Experimental hematology 33 (6), 624-631, 2005 | 55 | 2005 |
| Identification of a peptide for systemic brain delivery of a morpholino oligonucleotide in mouse models of spinal muscular atrophy F Shabanpoor, SM Hammond, F Abendroth, G Hazell, MJA Wood, MJ Gait nucleic acid therapeutics 27 (3), 130-143, 2017 | 52 | 2017 |
| Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia SM Hammond, SC Crable, KP Anderson Leukemia research 29 (1), 89-97, 2005 | 50 | 2005 |
| Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice LM Walter, MO Deguise, KE Meijboom, CA Betts, N Ahlskog, ... EBioMedicine, 2018 | 47 | 2018 |
| Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified Oligonucleotides SM Hammond, G McClorey, JZ Nordin, C Godfrey, S Stenler, KA Lennox, ... Molecular Therapy—Nucleic Acids 3 (11), e212, 2014 | 46 | 2014 |
| Antibody-oligonucleotide conjugate achieves CNS delivery in animal models for spinal muscular atrophy SM Hammond, F Abendroth, L Goli, J Stoodley, M Burrell, G Thom, ... JCI insight 7 (24), 2022 | 28* | 2022 |
| Peptide Nanoparticle Delivery of Charge-Neutral Splice-Switching Morpholino Oligonucleotides P Järver, EM Zaghloul, AA Arzumanov, AF Saleh, G McClorey, ... Nucleic acid therapeutics 25 (2), 65-77, 2015 | 23 | 2015 |
| Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization SM Hammond, OV Sergeeva, PA Melnikov, L Goli, J Stoodley, ... nucleic acid therapeutics 31 (3), 190-200, 2021 | 19 | 2021 |
